Federal health officials are targeting telehealth companies, notably Hims & Hers, for promoting unapproved versions of prescription drugs, including weight loss medications, as part of a crackdown on misleading pharmaceutical advertising. The FDA issued over 100 letters warning these companies to stop using false claims about their products, emphasizing the necessity for truthful advertising in compliance with new directives from the Trump administration.
Want More Context? 🔎






